A practical reference on REV-ERB agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-04. Anything still debated is marked as such rather than presented as settled.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Promethium is the only lanthanide and one of only two elements among the first 83 with no stable or long-lived (primordial) isotopes. This is a result of a rarely occurring effect of the liquid drop model of the nucleus and stabilities of neighbor element isotopes; it is also the least stable element of the first 84 elements. The primary decay products are neodymium and samarium isotopes (promethium-146 decays to both, the lighter isotopes generally to neodymium via positron decay and electron capture, and the heavier isotopes to samarium via beta decay). Promethium nuclear isomers may decay to other promethium isotopes and one isotope (145Pm) has a very rare alpha decay mode to stable praseodymium-141. The most stable isotope of the element is promethium-145, which has a specific activity of 139 Ci/g (5.1 TBq/g) and a half-life of 17.7 years via electron capture. Because it has 84 neutrons (two more than 82, which is a magic number corresponding to a stable neutron configuration), it may emit an alpha particle (which has 2 neutrons) to form praseodymium-141 with 82 neutrons. Thus, it is the only promethium isotope with an experimentally observed alpha decay. Its partial half-life for alpha decay is about 6.3×109 years, and the relative probability for a 145Pm nucleus to decay in this way is 2.8×10−7 %. Several other promethium isotopes such as 144Pm, 146Pm, and 147Pm also have a positive energy release for alpha decay; their alpha decays are predicted to occur but have not been observed. In total, 41 isotopes of promethium are known, ranging from 126Pm to 166Pm.
== Shotgun proteomics == Modern tandem mass spectrometry (MS) instruments combine features of fast duty cycle, exquisite sensitivity, and unprecedented mass accuracy. Tandem mass spectrometry, which is an ideal match for the large-scale protein identification and quantification in complex biological systems. In a shotgun proteomics approach, proteins in a complex mixture are digested by proteolytic enzymes such as trypsin. Subsequently, one or more chromatographic separations are applied to resolve resulting peptides, which are then ionized and analyzed in a mass spectrometer. To acquire tandem mass spectra, a particular peptide precursor is isolated, and fragmented in a mass spectrometer; the mass spectra corresponding to the fragments of peptide precursor is recorded. Tandem mass spectra contains specific information regarding the sequence of the peptide precursor, which can aid the identification of the peptide/protein.
On July 13, 2024, Trump survived an assassination attempt while addressing a campaign rally near Butler, Pennsylvania. Trump was shot at by Thomas Crooks, a 20-year-old man from Bethel Park, Pennsylvania, who fired eight rounds with an AR-15–style rifle from the roof of a building located approximately 400 feet (120 meters) from the stage. According to the FBI, Trump was hit by a bullet, and injured in his upper right ear. He raised a hand to his ear before dropping down on his podium behind the lectern for cover. Secret Service agents lunged toward Trump and shielded him. After the assailant was declared "down", agents helped Trump get up. Blood was visible on his ear and face. He asked the Secret Service agents to let him get his shoes. According to Trump, the agents "hit me so hard that my shoes fell off, and my shoes are tight." As of October 12, 2024, none of the medical records pertaining to his wounds had been released. In July 2024, psychologist Simon McCarthy-Jones of Trinity College Dublin said in The Conversation that "the potential effect of the attempted assassination of Trump upon Trump's mental health – whether negligible, negative or positive – cannot be ignored". McCarthy-Jones stated that Trump being an extrovert might improve his ability to deal with the psychological impact of the event.
Sources: en.wikipedia.org
=== Diagnostic biomarkers === Guidelines outlining requirements for inclusion of soluble biomarkers in osteoarthritis clinical trials were published in 2015, but there are no validated biomarkers used clinically to detect osteoarthritis, as of 2021. A 2015 systematic review of biomarkers for osteoarthritis, looking for molecules that could be used for risk assessments, found 37 different biochemical markers of bone and cartilage turnover in 25 publications. The strongest evidence was for urinary C-terminal telopeptide of type II collagen (uCTX-II) as a prognostic marker for knee osteoarthritis progression, and serum cartilage oligomeric matrix protein (COMP) levels as a prognostic marker for incidence of both knee and hip osteoarthritis. A review of biomarkers in hip osteoarthritis also found associations with uCTX-II. Procollagen type II C-terminal propeptide (PIICP) levels reflect type II collagen synthesis in body and within joint fluid PIICP levels can be used as a prognostic marker for early osteoarthritis.
The companies claimed that this machine could peel and cut an avocado in less than 30 seconds and operate unattended on a large batch, which could significantly reduce the time and labor required to prepare large quantities of guacamole. Chipotle's share price fell more than 9% after fiscal second quarter results showed same-store sales shrinking by 4%, compared to 0.4% in the prior quarter. In April 2025, Chipotle announced the opening of a location in Mexico by early 2026, looking to expand into new markets in the region. In August 2025, Chipotle announced plans of delivering food via drone aircraft within the greater Dallas area through a partnership with Zipline. In July 2026, Chipotle opened its first restaurant in Mexico in San Pedro Garza Garcia, Nuevo Leon, in partnership with Alsea. The company planned additional restaurants in Nuevo Leon during 2026 and an expansion into Mexico City in 2027. In August 2026, Chipotle opened its first restaurant in Saudi Arabia, in Riyadh, through a franchise partnership with Alshaya Group. In September 2026, Chipotle opened its first restaurant in South Korea, in the Gangnam District, via a joint venture with SPC Group.
==== United States ==== Mephedrone has been implicated in the death of a 22-year-old man, who had also injected black tar heroin. Mephedrone was found in his blood at a concentration of 0.50 mg/L and in his urine at a concentration of 198 mg/L. The blood concentration of morphine, a metabolite of heroin, was 0.06 mg/L. For comparison, the average blood morphine concentration resulting from deadly overdoses involving only heroin is around 0.34 mg/L.
Sources: en.wikipedia.org
The London and Home Counties Traffic Advisory Committee was established in 1924 to advise the Minister of Transport on issues concerning traffic and transport in the London Traffic Area. It was abolished in 1965. The purpose of the committee, as stated in the Act was "giving advice and assistance in manner provided by this Act to the Minister of Transport... in connection with the exercise and performance of his powers and duties in relation to traffic within the... London Traffic Area..."
==== Sirenia research ==== Saha, Bhardwaj & Bajpai (2026) study the restructuring of the sirenian skull throughout the evolutionary history of the group on the basis of data from extant and fossil taxa. Wagner et al. (2026) provide a methodology for quantification of the degree of pachyostosis in ribs and vertebrae of sirenians on the basis of the study of extant and extinct taxa. Pérez-Ramos et al. (2026) present a virtual reconstruction of the vertebral column of Pezosiren portelli. New fossil material of sirenians with dugongid affinities, associated with an invertebrate assemblage that might be indicative of presence of seagrass habitats, is described from the Oligocene strata of the Maniyara Fort Formation (India) by Joshi et al. (2026). Shinmura & Sawada (2026) reconstruct diets of sirenians from Miocene to Pliocene marine sediments in Hokkaido (Japan) on the basis of stable carbon isotope ratios of fatty acids and sterols extracted from their bones, providing evidence of Metaxytherium feeding on seagrass and evidence of feeding of Dusisiren and the Takikawa sea cow on seaweed.
An official post-mortem report by a regional chief physician noted that the period of forensic psychiatric care had devastating consequences the patient never recovered from. On January 17, 2020, a video titled "Medical Help" was uploaded to YouTube by 26-year-old Wail Ardab of Palatka, Florida, who developed severe dystonia and insomnia after taking Invega Trinza injections. On March 5, 2020, Ardab committed suicide by jumping from Memorial Bridge in Palatka. On December 28, 2021, 19-year-old Peyton Moyer fatally shot his mother and her boyfriend in Watkinsville, Georgia, while under the influence of the long-acting injectable antipsychotic paliperidone palmitate (Invega Sustenna). On November 2, 2023, Moyer was sentenced to life in prison. His family has alleged that Moyer had autism and was hospitalized for methamphetamine-induced psychosis at age 15 after he had been given methamphetamine by his maternal uncle; he then began receiving monthly injections of paliperidone palmitate, a drug not approved for use in patients under 18, without the consent of his father, who was his legal guardian. His family attributes the homicides to a rebound psychosis they say was triggered by the Invega Sustenna injections.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.